Please assess the completion status of the following clinical trial:

Trial Title: Study in Genotype 2 or 3 Patients With Chronic Hepatitis Virus Infection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Key Inclusion Criteria:~* Participants chronically infected with hepatitis C virus (HCV) genotype 2 or 3~* No previous exposure to an interferon formulation (ie, interferon alfa, pegylated interferon alfa-2a ) or ribavirin~* Body mass index (BMI) of 18 to 35 kg/m\^2, inclusive. BMI=weight (kg)/height (m)\^2~* Males and females, 18 - 70 years of age~Key Exclusion Criteria:~* Liver transplant recipients~* Documented or suspected hepatocellular carcinoma~* Evidence of decompensated cirrhosis~* History of chronic hepatitis B virus (HBV). Patients with resolved HBV infection may participate~* Current or known history of cancer~* Any gastrointestinal disease or surgical procedure that may impact the absorption of study drug~* Inability to tolerate oral medication~* Poor venous access~* Severe psychiatric disease~* History of chronic pulmonary disease~* History of cardiomyopathy, coronary artery disease (including angina), interventive procedure for coronary artery disease (including angioplasty, stent procedure, or cardiac bypass surgery), ventricular arrhythmia,, or other clinically significant cardiac disease~* History of or current electrocardiogram findings indicative of cardiovascular instability~* Preexisting ophthalmologic disorders considered clinically significant on eye~* History of uncontrolled diabetes mellitus~* Any known contraindication to pegylated interferon alfa-2a or ribavirin not otherwise specified.~* Positive hepatitis B virus surface antigen, HIV-1 or HIV-2 Ab~* Prior exposure to any HCV direct antiviral agent (eg, HCV protease, polymerase, previous nonstructural protein 5A inhibitors)~* Exposure to any investigational drug or placebo

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Control (Type: ACTIVE_COMPARATOR): Placebo + Pegylated interferon alfa-2a + Ribavirin
- 12 Week Cohort (Type: EXPERIMENTAL): Daclatasvir + Pegylated interferon alfa-2a + Ribavirin
- 16 Week Cohort (Type: EXPERIMENTAL): Daclatasvir + Pegylated interferon alfa-2a + Ribavirin

Based on this trial design, predict the completion outcome and termination type (if applicable).